+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07107750

Phase 1 Study of Emavusertib with Cisplatin, Gemcitabine, and Durvalumab for Untreated Advanced or Metastatic Biliary Tract Cancer

Led by Washington University School of Medicine · Updated on 2026-04-03

48

Participants Needed

1

Research Sites

100 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of emavusertib CA-4948 with standard chemotherapy and immunotherapy in patients with untreated advanced or metastatic biliary tract cancer. The study is based on preclinical findings suggesting that inhibiting IRAK4 may weaken tumor survival signals and improve the effectiveness of chemo- and immunotherapies in this type of cancer. This is a Phase 1 trial designed to assess safety and dosing. The study begins with a dose escalation phase to find the appropriate dose of emavusertib combined with standard care drugs cisplatin, gemcitabine, and durvalumab. Once the dose is established, an expansion phase will treat patients with this combination for up to 8 cycles. Chemotherapy cisplatin and gemcitabine is given intravenously on days 1 and 8 of each 21-day cycle, while emavusertib is taken orally twice daily. Durvalumab is administered intravenously on day 1 of each cycle and continues as maintenance therapy with emavusertib after chemotherapy ends. Participants will be monitored throughout treatment cycles with assessments including safety evaluations, laboratory tests, and imaging to measure tumor response according to RECIST criteria. The primary outcomes focus on safety and determining the right dose of emavusertib. Secondary outcomes include progression-free rate, disease control rate, overall response, progression-free survival, and overall survival. Participation may last over a year with follow-up to monitor long-term effects and treatment outcomes.

CONDITIONS

Brief Title

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Research Team

O

Olivia Aranha, M.D., Ph.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here